COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI).

COVID-19 SARS-CoV-2 allergen immunotherapy allergic rhinitis asthma

Journal

Allergologie select
ISSN: 2512-8957
Titre abrégé: Allergol Select
Pays: Germany
ID NLM: 101722686

Informations de publication

Date de publication:
2021
Historique:
received: 01 04 2021
accepted: 11 06 2021
entrez: 17 9 2021
pubmed: 18 9 2021
medline: 18 9 2021
Statut: epublish

Résumé

Vaccinations against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are intended to induce an immune response to protect against infection/disease. Allergen immunotherapy (AIT) is thought to induce a (different) immune response, e.g., to induce tolerance to allergens. In this position paper we clarify how to use AIT in temporal relation to COVID-19 vaccination. Four SARS-CoV-2 vaccines are currently approved in the EU, and their possible immunological interactions with AIT are described together with practical recommendations for use. Based on the internationally published literature, this position paper provides specific recommendations for the use of AIT in temporal relation to a SARS-CoV-2 vaccination. AIT is used in 1) allergic rhinitis, 2) allergic bronchial asthma, 3) insect venom allergy, 4) food allergy (peanut). For the continuation of an ongoing AIT, we recommend an interval of 1 week before and after vaccination for subcutaneous immunotherapy (SCIT). For sublingual immunotherapy (SLIT) and oral immunotherapy (OIT), we recommend taking them up to the day before vaccination and a break of 2 - 7 days after vaccination. Initiation of a new SCIT, SLIT, or OIT should be delayed until 1 week after the day of the second vaccination. For SCIT, we generally recommend an interval of ~ 1 week to COVID-19 vaccination.

Sections du résumé

BACKGROUND BACKGROUND
Vaccinations against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are intended to induce an immune response to protect against infection/disease. Allergen immunotherapy (AIT) is thought to induce a (different) immune response, e.g., to induce tolerance to allergens. In this position paper we clarify how to use AIT in temporal relation to COVID-19 vaccination. Four SARS-CoV-2 vaccines are currently approved in the EU, and their possible immunological interactions with AIT are described together with practical recommendations for use.
MATERIALS AND METHODS METHODS
Based on the internationally published literature, this position paper provides specific recommendations for the use of AIT in temporal relation to a SARS-CoV-2 vaccination.
RESULTS RESULTS
AIT is used in 1) allergic rhinitis, 2) allergic bronchial asthma, 3) insect venom allergy, 4) food allergy (peanut).
CONCLUSION CONCLUSIONS
For the continuation of an ongoing AIT, we recommend an interval of 1 week before and after vaccination for subcutaneous immunotherapy (SCIT). For sublingual immunotherapy (SLIT) and oral immunotherapy (OIT), we recommend taking them up to the day before vaccination and a break of 2 - 7 days after vaccination. Initiation of a new SCIT, SLIT, or OIT should be delayed until 1 week after the day of the second vaccination. For SCIT, we generally recommend an interval of ~ 1 week to COVID-19 vaccination.

Identifiants

pubmed: 34533543
doi: 10.5414/ALX02245E
pmc: PMC8439106
doi:

Types de publication

Journal Article

Langues

eng

Pagination

251-259

Informations de copyright

© Dustri-Verlag Dr. K. Feistle.

Références

Allergy. 2020 Nov;75(11):2764-2774
pubmed: 32500526
Pediatr Allergy Immunol. 2017 Nov;28(7):628-640
pubmed: 28779496
Allergy. 2021 Mar;76(3):648-676
pubmed: 32531110
Allergo J. 2020;29(3):17-25
pubmed: 32362727
Allergy. 2020 Jul;75(7):1546-1554
pubmed: 32329930
Allergy. 2019 Feb;74(2):349-360
pubmed: 30003552
Allergo J Int. 2021;30(2):51-55
pubmed: 33643776
Allergol Select. 2020 May 28;4:44-52
pubmed: 32568272
Allergy. 2021 Mar 3;:
pubmed: 33657648
Lancet. 2019 Jun 1;393(10187):2222-2232
pubmed: 31030987
J Allergy Clin Immunol. 2012 Aug;130(2):489-95
pubmed: 22766097
Lancet Infect Dis. 2021 Feb;21(2):e26-e35
pubmed: 33125914
Allergy. 2021 Apr;76(4):1199-1212
pubmed: 32813887
J Allergy Clin Immunol. 2011 Jan;127(1):3-7
pubmed: 21211638
J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5
pubmed: 32224232
Allergy. 2017 Mar;72(3):342-365
pubmed: 28120424
J Allergy Clin Immunol. 2018 Feb;141(2):463-472
pubmed: 29413255
Health Technol Assess. 2013 Jul;17(27):vi, xi-xiv, 1-322
pubmed: 23827204
J Allergy Clin Immunol Pract. 2019 Feb;7(2):479-491.e10
pubmed: 30423449
Allergy. 2017 Nov;72(11):1597-1631
pubmed: 28493631
Allergy. 2021 Jun;76(6):1617-1618
pubmed: 33320974
Ital J Pediatr. 2020 Jun 16;46(1):84
pubmed: 32546234
Allergy. 2021 Aug;76(8):2354-2366
pubmed: 33730365
J Allergy Clin Immunol. 2016 Feb;137(2):358-68
pubmed: 26853128
Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):591-601
pubmed: 33002895
J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558-62
pubmed: 9802362
Allergy. 2020 Oct;75(10):2503-2541
pubmed: 32535955
Pediatr Allergy Immunol. 2013 Sep;24(6):521-6
pubmed: 23902374
Immunity. 2021 Feb 9;54(2):291-307.e7
pubmed: 33450188
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Allergo J Int. 2021;30(1):1-25
pubmed: 33527068
Allergol Int. 2013 Dec;62(4):425-33
pubmed: 24153333
Clin Transl Allergy. 2017 Aug 8;7:24
pubmed: 28794855
J Allergy Clin Immunol. 2021 May;147(5):1865-1877
pubmed: 33039478
J Am Acad Dermatol. 2019 Jan;80(1):158-167.e1
pubmed: 30092324
Allergy. 2021 Jun;76(6):1621-1623
pubmed: 33432606
Allergo J. 2020;29(3):3
pubmed: 32362725
Allergy. 2021 Mar 2;:
pubmed: 33655519
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Nat Rev Immunol. 2021 Feb;21(2):83-100
pubmed: 33353987
MMW Fortschr Med. 2021 Jan;163(1):48-51
pubmed: 33464512
Allergy. 2021 Apr 2;:
pubmed: 33811358
Am J Respir Crit Care Med. 2017 Oct 15;196(8):985-992
pubmed: 28608756
J Allergy Clin Immunol. 2012 Mar;129(3):717-725.e5
pubmed: 22285278
Immunol Allergy Clin North Am. 2014 Aug;34(3):597-613, ix
pubmed: 25017679
Allergy. 2018 Feb;73(2):269-283
pubmed: 28718981
Allergol Select. 2021 Apr 1;5:140-147
pubmed: 33842829
J Asthma Allergy. 2018 Nov 20;11:181-192
pubmed: 30510434
Allergy. 2021 Mar;76(3):622-625
pubmed: 32589296
Allergo J. 2020;29(7):16-26
pubmed: 33162681
Allergy. 2017 Dec;72(12):1825-1848
pubmed: 28543086
World Allergy Organ J. 2016 Sep 16;9(1):32
pubmed: 27679682
Oncogene. 2017 Mar;36(11):1573-1584
pubmed: 27617580
Allergo J. 2020;29(4):14-27
pubmed: 32546898

Auteurs

Ludger Klimek (L)

Center for Rhinology and Allergology, Wiesbaden.

Oliver Pfaar (O)

Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg.

Eckard Hamelmann (E)

University Hospital for Pediatrics and Adolescent Medicine, Children's Center Bethel, University of Bielefeld.

Jörg Kleine-Tebbe (J)

Allergy Center Westend, Berlin.

Christian Taube (C)

Department of Pneumology, University Hospital Essen - Ruhrlandklinik, Essen.

Martin Wagenmann (M)

Department of Otorhinolaryngology, University Hospital Düsseldorf, Düsseldorf.

Thomas Werfel (T)

Department of Dermatology, Allergology and Venerology, Hanover Medical School.

Randolf Brehler (R)

Center for Rhinology and Allergology, Wiesbaden.
Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg.
University Hospital for Pediatrics and Adolescent Medicine, Children's Center Bethel, University of Bielefeld.
Allergy Center Westend, Berlin.
Department of Pneumology, University Hospital Essen - Ruhrlandklinik, Essen.
Department of Otorhinolaryngology, University Hospital Düsseldorf, Düsseldorf.
Department of Dermatology, Allergology and Venerology, Hanover Medical School.
Department of Dermatology, University Hospital Münster, Division of Allergology, Occupational Dermatology and Environmental Medicine, Münster.
Department of Dermatology and Allergy, Polyclinic for Dermatology and Allergology, Bonn.
Asthma and Allergy Center, Leverkusen.
Clinic for Otorhinolaryngology, University Hospital, Tübingen, and.
Allergology and Immunology, Clinic for Dermatotology, Venerology and Allergology, Charité Universitätsmedizin Berlin, Germany.

Natalija Novak (N)

Department of Dermatology and Allergy, Polyclinic for Dermatology and Allergology, Bonn.

Norbert Mülleneisen (N)

Asthma and Allergy Center, Leverkusen.

Sven Becker (S)

Clinic for Otorhinolaryngology, University Hospital, Tübingen, and.

Margitta Worm (M)

Allergology and Immunology, Clinic for Dermatotology, Venerology and Allergology, Charité Universitätsmedizin Berlin, Germany.

Classifications MeSH